Hormonal
Regular supervised walking significantly improves glycemic control (HbA1c) in type 2 diabetes patients, with supervised programs showing statistically significant benefits compared to non-supervised ones.
If you have Type 2 Diabetes, aim for at least 150 minutes of moderate walking per week, spread over at least three days. Supervised walking programs appear to offer better glycemic control than unsupervised efforts. If you cannot commit to long sessions, try breaking up long periods of sitting with short walks every 30 minutes.
The results of this meta-analysis supported the conclusion that walking is effective in decreasing HbA1c, by an average of 0.50%... a predefined subgroup analysis showed that a statistically significant improvement in HbA1c, by an average of 0.58%... was seen especially when intervention was supervised, whereas the change did not reach statistical significance in non-supervised studies.
Why this rating
Based on a meta-analysis of 20 RCTs, but studies were small and short-term.
Source
Walking for subjects with type 2 diabetes: a systematic review and joint AMD/SID/SISMES evidence-based practical guideline
P. Moghetti et al. · Sport Sciences for Health · 2020
DOI 10.1007/s11332-020-00690-y
More from this paper
- Short bouts of walking used to interrupt prolonged sitting improve glucose profiles in sedentary T2DM patients.Moderate
- Interval walking (alternating fast and slow speeds) improves glucose effectiveness and insulin sensitivity more effectively than continuous walking of matched energy expenditure in T2DM patients.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →